144 related articles for article (PubMed ID: 31753697)
1. Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs.
Anifowose A; Yuan Z; Yang X; Pan Z; Zheng Y; Zhang Z; Wang B
Bioorg Med Chem Lett; 2020 Jan; 30(2):126786. PubMed ID: 31753697
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs.
Draganov AB; Yang X; Anifowose A; De La Cruz LKC; Dai C; Ni N; Chen W; De Los Santos Z; Gu L; Zhou M; Wang B
Bioorg Med Chem; 2019 Sep; 27(17):3860-3865. PubMed ID: 31324563
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core.
Tripathi R; Anifowose A; Lu W; Yang X; Wang B
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2370-2381. PubMed ID: 36043494
[TBL] [Abstract][Full Text] [Related]
4. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
7. Investigation of amino acid conjugates of (S)-1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282) as water soluble anticancer prodrugs.
Lee KC; Venkateswararao E; Sharma VK; Jung SH
Eur J Med Chem; 2014 Jun; 80():439-46. PubMed ID: 24796884
[TBL] [Abstract][Full Text] [Related]
8. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
Li X; Liu C; Chen S; Hu H; Su J; Zou Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines.
Monteiro AS; Almeida J; Cabral G; Severino P; Videira PA; Sousa A; Nunes R; Pereira JD; Francisco AP; Perry MJ; Mendes E
Eur J Med Chem; 2013; 70():1-9. PubMed ID: 24125877
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2017; 12(12):e0189379. PubMed ID: 29228061
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyl Group Difference between Anthraquinone Derivatives Regulate Different Cell Death Pathways via Nucleo-Cytoplasmic Shuttling of p53.
Kamil M; Haque E; Mir SS; Irfan S; Hasan A; Sheikh S; Alam S; Ansari KM; Nazir A
Anticancer Agents Med Chem; 2019; 19(2):184-193. PubMed ID: 30370860
[TBL] [Abstract][Full Text] [Related]
13. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
[TBL] [Abstract][Full Text] [Related]
14. Prolidase as a prodrug converting enzyme. II. Synthesis of proline analogue of anthraquinone-2-carboxylic acid and its susceptibility to the action of prolidase.
Bielawska A; Bielawski K; Pałka J
Rocz Akad Med Bialymst; 1998; 43():201-9. PubMed ID: 9972056
[TBL] [Abstract][Full Text] [Related]
15. Discovery of SCY45, a Natural Small-Molecule MDM2-p53 Interaction Inhibitor.
Gong H; An J; Dong Q; Li J; Yang W; Sun W; Su Z; Zhang S
Chem Biodivers; 2019 Jun; 16(6):e1900081. PubMed ID: 30989812
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
[TBL] [Abstract][Full Text] [Related]
17. Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.
Nardinocchi L; Puca R; Givol D; D'Orazi G
FEBS Lett; 2010 Oct; 584(19):4253-8. PubMed ID: 20849851
[TBL] [Abstract][Full Text] [Related]
18. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.
Gu L; Zhang H; Liu T; Draganov A; Yi S; Wang B; Zhou M
Mol Cancer Ther; 2018 Feb; 17(2):497-507. PubMed ID: 29282301
[TBL] [Abstract][Full Text] [Related]
20. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
